Table 1.
HD | Study | Sample origin | Result | Notes |
---|---|---|---|---|
Autoimmune/paraneoplastic studies | ||||
2 | Mayo encephalopathy/autoimmune evaluation | Serum | Negative | |
2 | Mayo encephalopathy/autoimmune evaluation | CSF | Negative | Additionally negative on HD18, 31 |
2 | ANA | Serum | Negative | Additionally negative on HD16 |
2 | ANCA | Serum | Negative | |
2 | Oligoclonal banding | Serum | Negative | Additionally negative on HD18 |
2 | Oligoclonal banding | CSF | Negative | Additionally negative on HD18, 31 |
15 | Thyroperoxidase antibody | Serum | Negative | |
15 | Antithyroglobulin | Serum | Negative | |
16 | Mayo encephalopathy/autoimmune evaluation | Serum | Positive for N‐type calcium channel antibody 1 | |
16 | SSA antibody | Serum | Negative | |
16 | SSB antibody | Serum | Negative | |
16 | Smith antibody | Serum | Negative | |
16 | RNP antibody | Serum | Negative | |
16 | Anti‐DNA (double stranded) antibody | Serum | Negative | |
18 | Mayo Paraneoplastic/Autoantibody Evaluation | CSF | Negative | Additionally negative on HD31 |
30 | Voltage‐Gated Potassium Channel Antibody | Serum | Negative | |
30 | Mayo Encephalopathy/Autoimmune Evaluation | Serum | Positive for GAD65 Antibody and N‐type Calcium Channel Antibody 1 | |
Metabolic studies | ||||
1 | TSH | Serum | Within normal limits | |
2 | Free T4 | Serum | Within normal limits | |
10 | TSH | Serum | Within normal limits | |
Neoplastic studies | ||||
2 | CSF flow cytometry | CSF | No evidence of immunophenotypic abnormalities | |
2 | CSF cytology | CSF | Negative for malignant cells | |
3 | Neuron‐specific enolase | Serum | Negative | |
31 | Flow cytometry, peripheral blood | Blood | Within normal limits | |
Infectious studies | ||||
1 | COVID‐19 PCR | Nasopharyngeal | Negative | Additionally negative on HD15, 25 |
2 | Ehrlichia/anaplasma PCR | Serum | Negative | |
2 | West Nile virus PCR | CSF | Negative | |
2 | Enterovirus PCR | CSF | Negative | |
2 | Eastern equine encephalitis IgG, IgM | CSF | Negative | Additionally negative on HD18 |
2 | Epstein–Barr virus, IgM | Serum | Equivocal | |
2 | Epstein–Barr virus, IgG | Serum | Positive | |
2 | Varicella Zoster virus PCR | CSF | Negative | Additionally negative on HD18 |
2 | Herpes simplex virus 1/2 PCR | CSF | Negative | Additionally negative on HD18 |
2 | Cryptococcal antigen | CSF | Negative | |
2 | Lyme IgG | CSF | Negative | |
2 | VDRL | CSF | Negative | |
17 | HIV 1/2 antigen and antibody | Serum | Negative | |
31 | RT‐QuIC for sporadic Creutzfeldt–Jakob disease | CSF | Negative | |
Toxicology studies | ||||
1 | Toxicology screen | Urine | Positive for benzodiazepines | Had been treated with lorazepam |
Table of notable autoimmune, paraneoplastic, metabolic, neoplastic, and infectious studies that were conducted. CSF, cerebrospinal fluid. HD, hospital day.
Note that positive serum tests for GAD65 and N‐type calcium channel antibody were considered false positives in the setting of prior IVIG administration.